Search Within

Pallawi Torka

Formats
  1. Meeting Abstract (43)
  2. Journal Article (14)
  3. Research Letter (3)
  4. Correspondence (2)
  5. Editorial (1)
  6. Review (1)
Groups
  1. Center for Hematologic Malignancies (31)
  2. Department of Medicine (31)
  3. Hematologic Malignancies, Division of (31)
  4. Lymphoma (31)
  5. Hematology-Oncology Fellows (29)
  6. Sloan Kettering Institute Postdocs (28)

More Groups

People
  1. Paul Hamlin (30)
  2. Anita Kumar (28)
  3. Paola Ghione (28)
  4. Andrew Zelenetz (27)
  5. Gilles Salles (27)
  6. Lorenzo Falchi (27)

More People

Years
  1. 2025 (10)
  2. 2024 (27)
  3. 2023 (27)
Publications
  1. Blood (39)
  2. Blood Cancer Journal (4)
  3. Hematological Oncology (4)
  4. Blood Advances (3)
  5. Clinical Lymphoma, Myeloma and Leukemia (2)
  6. Journal of Clinical Oncology (2)

More Publications

Publishers
  1. American Society of Hematology (42)
  2. Elsevier Inc. (4)
  3. Nature Publishing Group (4)
  4. Wiley Blackwell (4)
  5. Biomed Central Ltd (3)
  6. American Society of Clinical Oncology (2)

More Publishers

Results (64)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • High grade B-cell lymphoma with MYC/BCL6-rearrangements (R) may have inferior outcomes compared to BCL2-R disease
    Meeting Abstract

    Healton, S. E.; Luttwak, E.; Rivas-Delgado, A.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; Hamlin, P. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • The predictive value of cell-of-origin subtype by Hans algorithm in 718 patients with large B cell lymphoma receiving polatuzumab vedotin
    Meeting Abstract

    Scheffer Cliff, E. R.; Pelaez, G. D.; Wan, F.; Iyengar, V.; Zhou, J.; Chung, K.; Abdel-Razeq, N.; Major, A.; Allen, J. M.; Sharp, J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin
    Meeting Abstract

    Moskowitz, A.; Shah, G. L.; Ganesan, N.; Chang, T.; Drill, E.; Davey, T.; Hancock, H.; Munayirji, B.; Douglas, M.; Santarosa, A. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Addition of monoclonal protein to MALT-IPI improved identification of MALT patients at high risk of progression with current first-line therapies
    Meeting Abstract

    Epperla, N.; Grover, N.; Torka, P.; Karmali, R.; Annunzio, K.; Watkins, M. P.; Anampa--Guzmán, A. C.; Reves, H.; Tavakkoli, M.; Christian, B.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Single-agent mosunetuzumab produces high complete response rates in patients with newly diagnosed follicular lymphoma: Primary analysis of the MITHIC-FL1 trial
    Meeting Abstract

    Falchi, L.; Okwali, M.; Ferreira Lopes, A.; Hamlin, P. A.; Lue, J. K.; Ghione, P.; Owens, C.; Torka, P.; Kumar, A.; Steiner, R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Representation of older adults in FDA and EMA registrational trials for diffuse large B cell lymphoma (DLBCL)
    Meeting Abstract

    Juthani, R.; Pugh, K.; Neuendorff, N.; Torka, P.
    Blood (2024)

    Fulltext@MSK | Save
  • Impact of the diagnosis-to-treatment interval (DTI) on outcomes in older adults with diffuse large B-cell lymphoma (DLBCL) treated in the real-world setting
    Meeting Abstract

    Hamlin, P. A.; Torka, P.; Hansen, E.; Belli, A. J.; Ambrose, J.; Zettler, C. M.; Fernandes, L. L.; Wiley, S.; Perry, B.; Wang, C. K.
    Blood (2024)

    Fulltext@MSK | Save
  • Molecular features are associated with disease stage in diffuse large B-cell lymphoma and reveal heterogeneity in patient outcomes
    Meeting Abstract

    Uppal, M.; Gurumurthi, A.; Hamlin, P. A.; Falchi, L.; Horwitz, S.; Kumar, A.; Noy, A.; Lue, J. K.; Torka, P.; Arcila, M. E.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Final response and survival results from a phase II trial of pembrolizumab and entinostat in relapsed/refractory Hodgkin lymphoma
    Meeting Abstract

    Stuver, R.; Vardhana, S. A.; Ganesan, N.; Boardman, A. P.; Caron, P.; Chang, T.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Representation of older adults in FDA and EMA registrational trials for acute myeloid leukemia (AML)
    Meeting Abstract

    Pugh, K.; Juthani, R.; Torka, P.; Neuendorff, N.
    Blood (2024)

    Fulltext@MSK | Save